For research use only. Not for therapeutic Use.
SC209, an ADC cytotoxin extracted from patent WO2021247798, is used in synthesis of anti-EGFR antibody-drug conjugate ADC. SC209 is a metabolite of STRO-002[1][2].
| Catalog Number | I044029 |
| CAS Number | 1977557-86-0 |
| Synonyms | (E,4S)-4-[[(2S)-2-[[(2S)-3-(3-aminophenyl)-3-methyl-2-(methylamino)butanoyl]amino]-3,3-dimethylbutanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid |
| Molecular Formula | C27H44N4O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C27H44N4O4/c1-16(2)20(14-17(3)25(34)35)31(10)24(33)22(26(4,5)6)30-23(32)21(29-9)27(7,8)18-12-11-13-19(28)15-18/h11-16,20-22,29H,28H2,1-10H3,(H,30,32)(H,34,35)/b17-14+/t20-,21-,22-/m1/s1 |
| InChIKey | ILRXQTICSGMLFH-ZYRIPLEJSA-N |
| SMILES | CC(C)C(C=C(C)C(=O)O)N(C)C(=O)C(C(C)(C)C)NC(=O)C(C(C)(C)C1=CC(=CC=C1)N)NC |
| Reference | [1]. Alice Yam, et al. Bispecific antibody-drug conjugates targeting egfr and muc1 and uses thereof. Patent. WO2021247798. [2]. De Almeida V, et al. Preclinical activity and safety of STRO-002, a novel ADC targeting folate receptor alpha for ovarian cancer. Gynecologic Oncology, 2018, 149: 50. |
